The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck (NYSE:MRK) announced Wednesday plans to conduct clinical trials to evaluate the efficacy and safety of a single-dose regimen of its human papillomavirus (HPV) vaccine, Gardasil 9.

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

millions of doses of Gardasil 9 have been distributed globally. Queen Mary has a lasting link with these patients: Professor Cuzick's work is explained to patients in the vaccine packaging leaflet, ...

The Gardasil® vaccine—called a “quadrivalent vaccine” because it protects against four HPV types (6, 11, 16, and 18)—was approved by the Food and Drug Administration in 2006 for girls and young women ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Gardasil is the new cervical vaccine developed by Sanofi Pasteur and Merck and found to be effective in its phase III trial, the vaccine is given in three doses over 6 months Gardasil is the new ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

Indications for GARDASIL 1 GARDASIL is a vaccine indicated in females 9 through 45 years of age. GARDASIL is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers caused by ...

This is indeed an important milestone in the development of strategies to combat cervical abnormalities; the worlds first ever vaccine for cervical cancer, named Gardasil, has made it to the market.